when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Fierce Biotech·21h ago·1 min read

BrainChild Bio masterminds $116M series A for CAR-T's pivotal push in pediatric brain cancer

Sep 7, 2026·read at Fierce Biotech ↗

A startup spawned from Seattle Children’s Hospital has raised a $116 million series A to advance cell therapies for devastating childhood brain tumors.

source

Reporting by Fierce Biotech.

read at Fierce Biotech ↗

sharex / twitter linkedin

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

7h agoNovartis’ centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 testFierce Biotech
1d agoNovo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrappedFierce Biotech
1d agoAbbVie-backed ADARx plans IPO to bankroll array of clinical-stage siRNA therapiesFierce Biotech
2d agoRoivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 winFierce Biotech
3d agoNovartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trialFierce Biotech